All Title Author
Keywords Abstract


A New Immunofluorescence Assay for Fecal Calprotectin Distinguishes Inflammatory Bowel Disease from Functional Bowel Disease

DOI: 10.4236/ojgas.2018.811042, PP. 405-414

Keywords: Inflammatory Bowel Disease, Functional Bowel Disease, Fecal Calprotectin

Full-Text   Cite this paper   Add to My Lib

Abstract:

Aims: To investigate the diagnostic value of fecal calprotectin (FC) determined by a new immunofluorescence assay-fluorescence enzyme immunoassay (FEIA) in patient with inflammatory bowel disease (IBD) or functional bowel disease, compared with the typical ELISA kit. Methods: FC was determined simultaneously by FEIA and an ELISA kit in 26 patients with functional bowel disease and 77 patients with IBD. We compared the difference of FC levels between patients with IBD and patients with functional bowel disease. Receiver operating characteristics curve (ROC) was constructed to obtain the optimal cut-off value of FC for distinguishing IBD from functional bowel disease and the corresponding sensitivity and specificity. Results: The median FC levels of patients with IBD in clinical active stage or clinical remission stage was significantly higher than that of patients with functional bowel disease. The median FC levels of patients with IBD in clinical active stage, IBD in clinical remission stage and functional bowel disease were as follow: 699.91 (346.14 ~ 1647.54) μg/g; 407.36 (121.81 ~ 878.48) μg/g; 39.04 (12.09 ~ 81.04) μg/g when FC was measured by FEIA. The median FC levels were 716.99 (240.42 ~ 1232.53) μg/g; 338.46 (53.08 ~ 692.82) μg/g; 41.44 (11.77 ~ 73.19) μg/g among such above three groups of patients respectively, when FC was measured by ELISA kit. The diagnostic value of IBD with FC determined by FEIA (optimal cut-off = 131.79 μg/g) and ELISA kit (optimal cut-off = 121.85 μg/g) presented an area under the curve of 0.881 and 0.873, respectively. Conclusions: FC determined by FEIA was an accurate surrogate marker to distinguish IBD from functional bowel disease.

References

[1]  Zeng, Z., Zhu, Z., Yang, Y., et al. (2013) Incidence and Clinical Characteristics of Inflammatory Bowel Disease in a Developed Region of Guangdong Province, China: A Prospective Population-Based Study. Journal of Gastroenterology and Hepatology, 28, 1148-1153.
https://doi.org/10.1111/jgh.12164
[2]  APDW 2004 Chinese IBD Working Group (2006) Retrospective Analysis of 515 Cases of Crohn’s Disease Hospitalization in China: Nationwide Study from 1990 to 2003. Journal of Gastroenterology and Hepatology, 21, 1009-1015.
https://doi.org/10.1111/j.1440-1746.2006.04140.x
[3]  Wang, Y. and Ouyang, Q. (2007) Ulcerative Colitis in China: Retrospective Analysis of 3100 Hospitalized Patients. Journal of Gastroenterology and Hepatology, 22, 1450-1455.
https://doi.org/10.1111/j.1440-1746.2007.04873.x
[4]  Roseth, A.G., Schmidt, P.N. and Fagerhol, M.K. (1999) Correlation between Faecal Excretion of Indium-111-Labelled Granulocytes and Calprotectin, a Granulocyte Marker Protein, in Patients with Inflammatory Bowel Disease. Scandinavian Journal of Gastroenterology, 34, 50-54.
https://doi.org/10.1080/00365529950172835
[5]  Kalantari, H., Taheri, A., Yaran, M., et al. (2015) Fecal Calprotectin Is a Useful Marker to Diagnose Ulcerative Colitis from Irritable Bowel Syndrome. Advanced Biomedical Research, 4, 85.
https://doi.org/10.4103/2277-9175.156647
[6]  Alibrahim, B., Aljasser, M.I., Salh, B., et al. (2015) Fecal Calprotectin Use in inflammatory Bowel Disease and Beyond: A Mini-Review. Canadian Journal of Gastroenterology and Hepatology, 29, 157-163.
https://doi.org/10.1155/2015/950286
[7]  The Society of Gastroenterology of the Chinese Medical Association (2012) Consensus on the Diagnosis and Treatment of Inflammatory Bowel Disease (2012•Guangzhou). Chinese Journal of Gastroenterology, 17, 763-781.
[8]  Peyrin-Biroulet, L., Loftus, E.V. Jr, Harmsen, W., et al. (2010) Cumulative Incidence of and Risk Factors for Major Abdominal Surgery in a Population-Based Cohort of Crohn’s Disease. Gastroenterology, 128, S1184.
[9]  Song, X.M., Gao, X., Li, M.Z., Chen, Z.H., Chen, S.C., Hu, P.J., et al. (2011) Clinical Features and Risk Factors for Primary Surgery in 205 Patients with Crohn’s Disease: Analysis of a South China Cohort. Diseases of the Colon & Rectum, 54, 1147-1154.
https://doi.org/10.1097/DCR.0b013e318222ddc3
[10]  Tibble, J.A., Sigthorsson, G., Foster, R., Forgacs, I. and Bjarnason, I. (2002) Use of Surrogate Markers of Inflammation and Rome Criteria to Distinguish Organic from Nonorganic Intestinal Disease. Gastroenterology, 123, 450-460.
https://doi.org/10.1053/gast.2002.34755
[11]  Van Rheenen, P.F., Van de Vijver, E. and Fidler, V. (2010) Faecal Calprotectin for Screening of Patients with Suspected Inflammatory Bowel Disease: Diagnostic Meta-Analysis. BMJ, 341, c3369.
https://doi.org/10.1136/bmj.c3369
[12]  Papadia, C., Maffei, E., Del Rio, P., Taylor, S., Caini, S., Montana, C., et al. (2013) Sensitivity and Specificity of Magnetic Resonance Enterography in the Clinical Management of Fistulizing Crohn’s Disease. Inflammatory Bowel Diseases, 19, 1896-1903.
[13]  Von Roon, A.C., Karamountzos, L., Purkayastha, S., et al. (2007) Diagnostic Precision of Fecal Calprotectin for Inflammatory Bowel Disease and Colorectal Malignancy. American Journal of Gastroenterology, 102, 803-813.
https://doi.org/10.1111/j.1572-0241.2007.01126.x
[14]  Ng, S.C., Tang, W., Ching, J.Y., Wong, M., Chow, C.M., et al. (2013) Incidence and Phenotype of Inflammatory Bowel Disease Based on Results from the Asia-Pacific Crohn’s and Colitis Epidemiology Study. Gastroenterology, 145, 158-165.
https://doi.org/10.1053/j.gastro.2013.04.007
[15]  Rugtveit, J. and Fagerhol, M.K. (2002) Age-Dependent Variations in Fecal Calprotectin Concentrations in Children. Journal of Pediatric Gastroenterology and Nutrition, 34, 323-325.
https://doi.org/10.1097/00005176-200203000-00022

Full-Text

comments powered by Disqus